Efficacy of TAK-085 in Participants With Hypertriglyceridemia

Status Completed

Clinical Trial Summary

The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.

Clinical Trial Description

TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)).

This is a phase 3, double-blind, randomized study to evaluate the efficacy and safety of TAK-085 compared to EPA-E in participants with hypertriglyceridemia who are undergoing lifestyle modification.

The study period is a total of 20 weeks, comprised of an 8- week screening period and 12 weeks of treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Hypertriglyceridemia

Clinical Trial Details

NCT number	NCT01350973
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	November 2009
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT02250105` - Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia	Phase 2
Completed	`NCT02859129` - Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)	Phase 1
Completed	`NCT01455844` - TRIal For Efficacy of Capre on hyperTriglyceridemiA	Phase 2
Completed	`NCT01437930` - Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients	N/A
Completed	`NCT00959842` - Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia	Phase 1/Phase 2
Completed	`NCT01010399` - Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects	Phase 4
Completed	`NCT00519714` - A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)	Phase 2/Phase 3
Recruiting	`NCT00186537` - Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.	N/A
Completed	`NCT00246402` - Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV	N/A
Completed	`NCT06020950` - Chia Seeds Consumption in Hypertriglyceridemia	N/A
Completed	`NCT02354976` - A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.	Phase 2
Completed	`NCT04966494` - Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women	N/A
Completed	`NCT04650152` - Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
Completed	`NCT04630366` - A Phase 1, First Time in Humans Study of NST-1024	Phase 1
Completed	`NCT03693131` - Efficacy of MND-2119 in Participants With Hypertriglyceridemia	Phase 3
Completed	`NCT04756180` - An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.	Phase 3
Completed	`NCT02868177` - Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes	Phase 2/Phase 3
Completed	`NCT01968720` - Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia	Phase 2
Completed	`NCT01462877` - A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic	Phase 4